ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Sullivan Will Be Secretary Most Knowledgeable About Cancer Program; Ihde Names ‘JNCI’ Editor

January 6, 1989

IOM Committee Advises DOD To Fund Grants; Training, Infrastrucure In Breast Cancer; Goals To Raise Number of New Investigators

May 21, 1993

President’s Budget Versus NCI’s Bypass: A Comparison

February 21, 1992

In Brief: Kovac, Bunn Lead AACI; Hollings Researcher Wins Immunology Award; Turrisi Moves To SC

September 16, 1994

NSABP Executive Committee Joins Fisher In Suit Against Pitt

August 5, 1994

PSA Level Predicts Survival For Prostate Cancer

October 25, 2002